

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A medical device for the treatment of atherosclerotic vulnerable plaque comprising: a stent configured to maintain vessel patency and to provide structural support for a fibrous cap of a vulnerable plaque lesion; a biocompatible vehicle affixed to at least a portion of the stent; and a combination of sirolimus ~~a rapamycin~~ and Panzem® ~~17-beta-estradiol~~, in therapeutic dosages, incorporated into the biocompatible vehicle for treating at least one of the fibrous cap and a lipid core of the vulnerable plaque lesion.
2. (Original) The medical device for the treatment of atherosclerotic vulnerable plaque according to claim 1, wherein the stent is balloon expandable.
3. (Original) The medical device for the treatment of atherosclerotic vulnerable plaque according to claim 1, wherein the stent is self-expanding.
4. (Original) The medical device for the treatment of atherosclerotic vulnerable plaque according to claim 1, wherein the biocompatible vehicle comprises a polymeric coating.
5. (Cancelled) The medical device for the treatment of atherosclerotic vulnerable plaque according to claim 1, wherein the rapamycin comprises sirolimus.